What Lifeward’s Payer Stack Actually Looks Like — And Why the Revenue Gap Matters

A competitor outlet recently covered the personal exoskeleton market and Lifeward Ltd. (Nasdaq: LFWD, formerly ReWalk Robotics). Our company intelligence database adds granular financial and regulatory context their reporting didn’t capture.

---

Our Data

Lifeward carries a Coverage Priority Score of 35 in our database — a WATCH rating, not a BUY — and the underlying numbers explain why that distinction matters.

The payer milestone stack is genuinely significant. CMS finalized a national Medicare reimbursement rate of $94,617 per unit effective April 1, 2024. By December 2025, UnitedHealthcare and Humana Medicare Advantage plans had issued prior authorization approvals. A first major U.S. commercial insurer followed in April 2025. An Administrative Law Judge ruled in June 2025 that ReWalk is “reasonable and necessary” for a Medicare beneficiary — establishing claims-level legal precedent. On the device side, ReWalk 7 received FDA 510(k) clearance in March 2025 and CE mark in September 2025, with push-button control and cloud connectivity that our analysis flags as material to reducing the 40–80 session training burden documented in early VA trials.

But the revenue data tells a more complicated story. Full-year 2024 revenue of $25.66M nearly doubled from $13.85M in 2023 — yet missed management’s own guidance of $28–32M. Q2 2025 came in at $5.7M (gross margin 43.9%); Q3 2025 at $6.2M (gross margin 43.7%, up from 36.2% in Q3 2024). Sequential improvement is real. Annualized run-rate, however, implies roughly $23–25M — below the 2024 full-year figure, reflecting AlterG international distributor timing variability that our signals database flagged as a recurring pattern.

Market cap sits at approximately $9M against trailing revenues near $25M — a P/S of roughly 0.38x — signaling that investors are pricing execution risk, not the payer milestone stack. Germany, which accounts for ~40% of exoskeleton sales with BARMER statutory coverage, remains the most durable revenue anchor in the portfolio.

---

What They Missed

The coverage gap in most exoskeleton reporting is the distance between a payer approval and a funded device in a patient’s hands. Our analysis identifies three structural friction points that the headline milestone narrative obscures.

First, claims processing latency: Medicare reimbursement at $94,617 per unit is finalized, but documentation requirements, medical necessity criteria, and prior authorization workflows gate actual cash collection. Approval is not revenue.

Second, training infrastructure as a scaling constraint: The 40–80 session training requirement documented in VA trials is not a solved problem. ReWalk 7’s usability improvements are directionally positive, but our WATCH thesis holds that profitable scaling requires demonstrated reduction in average training burden — data that has not yet been published at commercial scale.

Third, the Oramed governance overhang: The January 2026 transaction grants Oramed up to 49.9% beneficial ownership and introduces oral drug delivery IP (the POD platform) into a medical robotics company. CEO Mark Grant brings Medtronic diabetes commercial experience, which is relevant to payer navigation — but the strategic rationale for combining these platforms remains unresolved in any public disclosure we have reviewed. Ownership concentration at this level, in a micro-cap with persistent operating losses, is a material governance variable that competitor coverage has not weighted appropriately.

---

Bottom Line

Lifeward has built the most complete payer coverage stack in personal exoskeletons, but at a ~$9M market cap and with 2024 revenue missing its own guidance, the market is correctly demanding proof that approvals convert to funded devices at profitable volume — and that evidence is not yet in the data.